{"id":65718,"date":"2026-05-19T23:43:46","date_gmt":"2026-05-19T15:43:46","guid":{"rendered":"https:\/\/flcube.com\/?p=65718"},"modified":"2026-05-19T23:43:48","modified_gmt":"2026-05-19T15:43:48","slug":"henlius-biotech-secures-exclusive-china-rights-to-ctfhs-third-generation-egfr-tki-fhnd9041-for-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65718","title":{"rendered":"Henlius Biotech Secures Exclusive China Rights to CTFH&#8217;s Third-Generation EGFR TKI FHND9041 for NSCLC"},"content":{"rendered":"\n<p><strong>Shanghai Henlius Biotech, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a>) announced a <strong>strategic partnership<\/strong> with fellow Chinese biopharmaceutical company <strong>Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH)<\/strong> for the exclusive <strong>commercialization and development rights<\/strong> to <strong>FHND9041<\/strong>, a <strong>third-generation EGFR tyrosine kinase inhibitor (TKI)<\/strong>. The agreement grants Henlius exclusive rights in <strong>mainland China and Macau<\/strong>, plus <strong>priority negotiation rights<\/strong> for the <strong>U.S. and Japan<\/strong> markets, as the drug advances toward potential approval for <strong>first-line EGFR exon 19 deletion (19del) NSCLC<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-territorial-rights\">Deal Structure &amp; Territorial Rights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Territory<\/th><th>Rights Granted<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Mainland China &amp; Macau<\/strong><\/td><td>Exclusive commercialization and development rights<\/td><td>Access to world&#8217;s largest EGFR-mutated NSCLC market<\/td><\/tr><tr><td><strong>United States &amp; Japan<\/strong><\/td><td>Priority negotiation rights<\/td><td>Gateway to premium-priced markets with high unmet need<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>Undisclosed amount<\/td><td>Immediate value recognition for CTFH<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Sales-based milestones<\/td><td>Aligns incentives with commercial success<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered royalties on net sales<\/td><td>Ongoing revenue stream for CTFH<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-status-amp-clinical-indication\">Regulatory Status &amp; Clinical Indication<\/h2>\n\n\n\n<p>The partnership centers on <strong>FHND9041<\/strong>, which has achieved significant regulatory momentum:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NDA Status<\/strong>: <strong>Accepted by China&#8217;s NMPA<\/strong> in <strong>February 2026<\/strong><\/li>\n\n\n\n<li><strong>Proposed Indication<\/strong>: <strong>First-line treatment<\/strong> of <strong>non-small cell lung cancer (NSCLC)<\/strong> with <strong>EGFR exon 19 deletion (19del)<\/strong><\/li>\n\n\n\n<li><strong>Drug Class<\/strong>: <strong>Third-generation EGFR TKI<\/strong> designed to overcome resistance mutations while sparing wild-type EGFR<\/li>\n\n\n\n<li><strong>Market Timing<\/strong>: Potential approval decision expected in <strong>Q4 2026 or Q1 2027<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EGFR 19del Prevalence<\/strong>: Represents approximately <strong>45% of all EGFR mutations<\/strong> in NSCLC, affecting <strong>~60,000 patients annually<\/strong> in China<\/li>\n\n\n\n<li><strong>First-Line Setting<\/strong>: Highest-value indication with <strong>premium pricing<\/strong> and <strong>broad patient population<\/strong><\/li>\n\n\n\n<li><strong>Competitive Environment<\/strong>: Established players include <strong>osimertinib (Tagrisso\u00ae)<\/strong>, <strong>almonertinib<\/strong>, and <strong>furmonertinib<\/strong>, creating high-barrier but high-reward market<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong>: Peak annual sales in China could reach <strong>RMB 2-3 billion<\/strong> ($280-420 million) with successful market penetration<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-for-henlius\">Strategic Rationale for Henlius<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology Portfolio Expansion<\/strong>: Adds high-value targeted therapy to complement Henlius&#8217; existing biosimilars and innovative pipeline<\/li>\n\n\n\n<li><strong>Commercial Infrastructure Leverage<\/strong>: Utilizes Henlius&#8217; established <strong>oncology sales force<\/strong> and <strong>hospital relationships<\/strong><\/li>\n\n\n\n<li><strong>Innovation Credibility<\/strong>: Demonstrates commitment to <strong>innovative small molecule development<\/strong> beyond biologics<\/li>\n\n\n\n<li><strong>Global Ambition<\/strong>: Priority rights in U.S. and Japan support <strong>international expansion strategy<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-benefits-for-ctfh\">Strategic Benefits for CTFH<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Commercial Expertise<\/strong>: Partners with Henlius&#8217; proven <strong>oncology commercialization capabilities<\/strong> in China<\/li>\n\n\n\n<li><strong>Capital Efficiency<\/strong>: Reduces need for substantial investment in <strong>sales force and marketing infrastructure<\/strong><\/li>\n\n\n\n<li><strong>Risk Mitigation<\/strong>: Shares commercial risk while maintaining <strong>royalty upside<\/strong> on global sales<\/li>\n\n\n\n<li><strong>Focus Optimization<\/strong>: Allows CTFH to concentrate resources on <strong>pipeline development<\/strong> and <strong>manufacturing<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-third-generation-egfr-tki-differentiation\">Third-Generation EGFR TKI Differentiation<\/h2>\n\n\n\n<p>While specific differentiating features were not disclosed, third-generation EGFR TKIs typically offer:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>T790M Resistance Coverage<\/strong>: Activity against the common resistance mutation that develops with first-generation TKIs<\/li>\n\n\n\n<li><strong>Wild-Type Sparing<\/strong>: Reduced toxicity compared to earlier generations due to selectivity for mutant EGFR<\/li>\n\n\n\n<li><strong>CNS Penetration<\/strong>: Improved blood-brain barrier penetration for brain metastasis control<\/li>\n\n\n\n<li><strong>Dosing Convenience<\/strong>: Once-daily oral administration with manageable side effect profile<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-amp-commercial-timeline\">Development &amp; Commercial Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NDA Review<\/strong>: Currently under NMPA review with <strong>standard 12-month timeline<\/strong> from February 2026 acceptance<\/li>\n\n\n\n<li><strong>Launch Preparation<\/strong>: Henlius likely preparing <strong>commercial launch infrastructure<\/strong> for potential 2027 approval<\/li>\n\n\n\n<li><strong>Market Access Strategy<\/strong>: Pricing and reimbursement negotiations with Chinese healthcare authorities<\/li>\n\n\n\n<li><strong>Physician Education<\/strong>: Comprehensive medical affairs program to support appropriate patient identification and treatment initiation<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-positioning-strategy\">Competitive Positioning Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Price Competition<\/strong>: Potential to offer <strong>competitive pricing<\/strong> compared to premium-priced incumbents<\/li>\n\n\n\n<li><strong>Access Advantage<\/strong>: Strong relationships with <strong>Chinese hospitals and physicians<\/strong> through existing oncology portfolio<\/li>\n\n\n\n<li><strong>Combination Potential<\/strong>: Future studies may explore combinations with <strong>Henlius&#8217; immuno-oncology assets<\/strong><\/li>\n\n\n\n<li><strong>Patient Support<\/strong>: Comprehensive patient assistance programs to improve treatment access and adherence<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, commercial partnerships, and market opportunities for FHND9041. Actual results may differ due to risks including NDA approval outcomes, competitive dynamics, pricing pressures, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a strategic partnership with fellow Chinese biopharmaceutical company&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65720,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,2336,270,862,33],"class_list":["post-65718","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-chia-tai-fenghai-pharmaceutical","tag-henlius-biotech","tag-hkg-2696","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Henlius Biotech Secures Exclusive China Rights to CTFH&#039;s Third-Generation EGFR TKI FHND9041 for NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a strategic partnership with fellow Chinese biopharmaceutical company Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) for the exclusive commercialization and development rights to FHND9041, a third-generation EGFR tyrosine kinase inhibitor (TKI). The agreement grants Henlius exclusive rights in mainland China and Macau, plus priority negotiation rights for the U.S. and Japan markets, as the drug advances toward potential approval for first-line EGFR exon 19 deletion (19del) NSCLC.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65718\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Henlius Biotech Secures Exclusive China Rights to CTFH&#039;s Third-Generation EGFR TKI FHND9041 for NSCLC\" \/>\n<meta property=\"og:description\" content=\"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a strategic partnership with fellow Chinese biopharmaceutical company Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) for the exclusive commercialization and development rights to FHND9041, a third-generation EGFR tyrosine kinase inhibitor (TKI). The agreement grants Henlius exclusive rights in mainland China and Macau, plus priority negotiation rights for the U.S. and Japan markets, as the drug advances toward potential approval for first-line EGFR exon 19 deletion (19del) NSCLC.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65718\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-19T15:43:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-19T15:43:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1909.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65718#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65718\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Henlius Biotech Secures Exclusive China Rights to CTFH&#8217;s Third-Generation EGFR TKI FHND9041 for NSCLC\",\"datePublished\":\"2026-05-19T15:43:46+00:00\",\"dateModified\":\"2026-05-19T15:43:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65718\"},\"wordCount\":604,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65718#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1909.webp\",\"keywords\":[\"Cancer\",\"Chia Tai Fenghai Pharmaceutical\",\"Henlius Biotech\",\"HKG: 2696\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65718#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65718\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65718\",\"name\":\"Henlius Biotech Secures Exclusive China Rights to CTFH's Third-Generation EGFR TKI FHND9041 for NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65718#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65718#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1909.webp\",\"datePublished\":\"2026-05-19T15:43:46+00:00\",\"dateModified\":\"2026-05-19T15:43:48+00:00\",\"description\":\"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a strategic partnership with fellow Chinese biopharmaceutical company Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) for the exclusive commercialization and development rights to FHND9041, a third-generation EGFR tyrosine kinase inhibitor (TKI). The agreement grants Henlius exclusive rights in mainland China and Macau, plus priority negotiation rights for the U.S. and Japan markets, as the drug advances toward potential approval for first-line EGFR exon 19 deletion (19del) NSCLC.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65718#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65718\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65718#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1909.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1909.webp\",\"width\":1080,\"height\":608,\"caption\":\"Henlius Biotech Secures Exclusive China Rights to CTFH's Third-Generation EGFR TKI FHND9041 for NSCLC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65718#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Henlius Biotech Secures Exclusive China Rights to CTFH&#8217;s Third-Generation EGFR TKI FHND9041 for NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Henlius Biotech Secures Exclusive China Rights to CTFH's Third-Generation EGFR TKI FHND9041 for NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a strategic partnership with fellow Chinese biopharmaceutical company Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) for the exclusive commercialization and development rights to FHND9041, a third-generation EGFR tyrosine kinase inhibitor (TKI). The agreement grants Henlius exclusive rights in mainland China and Macau, plus priority negotiation rights for the U.S. and Japan markets, as the drug advances toward potential approval for first-line EGFR exon 19 deletion (19del) NSCLC.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65718","og_locale":"en_US","og_type":"article","og_title":"Henlius Biotech Secures Exclusive China Rights to CTFH's Third-Generation EGFR TKI FHND9041 for NSCLC","og_description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a strategic partnership with fellow Chinese biopharmaceutical company Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) for the exclusive commercialization and development rights to FHND9041, a third-generation EGFR tyrosine kinase inhibitor (TKI). The agreement grants Henlius exclusive rights in mainland China and Macau, plus priority negotiation rights for the U.S. and Japan markets, as the drug advances toward potential approval for first-line EGFR exon 19 deletion (19del) NSCLC.","og_url":"https:\/\/flcube.com\/?p=65718","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-19T15:43:46+00:00","article_modified_time":"2026-05-19T15:43:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1909.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65718#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65718"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Henlius Biotech Secures Exclusive China Rights to CTFH&#8217;s Third-Generation EGFR TKI FHND9041 for NSCLC","datePublished":"2026-05-19T15:43:46+00:00","dateModified":"2026-05-19T15:43:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65718"},"wordCount":604,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65718#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1909.webp","keywords":["Cancer","Chia Tai Fenghai Pharmaceutical","Henlius Biotech","HKG: 2696","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65718#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65718","url":"https:\/\/flcube.com\/?p=65718","name":"Henlius Biotech Secures Exclusive China Rights to CTFH's Third-Generation EGFR TKI FHND9041 for NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65718#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65718#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1909.webp","datePublished":"2026-05-19T15:43:46+00:00","dateModified":"2026-05-19T15:43:48+00:00","description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) announced a strategic partnership with fellow Chinese biopharmaceutical company Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH) for the exclusive commercialization and development rights to FHND9041, a third-generation EGFR tyrosine kinase inhibitor (TKI). The agreement grants Henlius exclusive rights in mainland China and Macau, plus priority negotiation rights for the U.S. and Japan markets, as the drug advances toward potential approval for first-line EGFR exon 19 deletion (19del) NSCLC.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65718#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65718"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65718#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1909.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1909.webp","width":1080,"height":608,"caption":"Henlius Biotech Secures Exclusive China Rights to CTFH's Third-Generation EGFR TKI FHND9041 for NSCLC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65718#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Henlius Biotech Secures Exclusive China Rights to CTFH&#8217;s Third-Generation EGFR TKI FHND9041 for NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1909.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65718"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65718\/revisions"}],"predecessor-version":[{"id":65721,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65718\/revisions\/65721"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65720"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}